Evidence & concentration worksheet · Brain Health & Nootropics
Semax 10 mg
Human efficacy and a validated dose have not been established for this compound. The former regimen has been withheld; only concentration arithmetic remains available.
Evidence review
No established human dosing protocol
Human efficacy and a validated dose have not been established for this compound. The former regimen has been withheld; only concentration arithmetic remains available.
How it works
Semax is a synthetic seven-amino-acid ACTH-fragment analogue with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. FDA treats Semax free base and Semax acetate as distinct bulk drug substances and found inconsistent naming in compounding nominations, so the exact material cannot be inferred from the word Semax alone.[1]
Semax is registered in Russia as nasal drops, but neither form is a component of an FDA-approved drug. Russian registration does not establish approval, product equivalence, or an accepted indication in the United States.[1]
Benefits & side effects
FDA's 2026 source review found insufficient evidence for Semax free base or acetate in cerebral ischemia, migraine, or trigeminal neuralgia. The clinical material available for those uses was sparse, poorly described, small, and in some cases showed no meaningful pain resolution; professional guidelines did not discuss Semax.[1]
A small placebo comparison reported short-term fMRI network changes after intranasal Semax, but a neuroimaging signal is not proof of improved memory, attention, mood, or daily function.[4] An older stroke publication is available only as limited Russian-language clinical literature and does not overcome the methodological gaps identified by FDA.[5]
Calculator
Concentration and measurement calculator
Use this only to check arithmetic from an authoritative product label, registered study protocol, or qualified clinician.
Arithmetic only — not a dose recommendation
Enter only a concentration and target supplied by an authoritative product label, a registered study protocol, or a qualified clinician. A correct conversion does not establish that a substance, vial, route, or dose is safe or effective.
Enter only a concentration and target supplied by an authoritative product label, a registered study protocol, or a qualified clinician. A correct conversion does not establish that a substance, vial, route, or dose is safe or effective.
Source concentration
Source-supplied target
References
References
- U.S. FDA — FDA evaluation of Semax-related bulk drug substances (2026)
- Brain Research — Semax regulates BDNF and TrkB expression in rat hippocampus (2006)
- BMC Genomics — Semax affects immune- and vascular-related gene expression in a rat focal-ischemia model (2014)
- Bulletin of Experimental Biology and Medicine — Effects of Semax on the default-mode network (2018)
- Zhurnal Nevrologii i Psikhiatrii — Effectiveness of Semax in acute hemispheric ischemic stroke (1997)
- U.S. FDA — July 2026 Pharmacy Compounding Advisory Committee meeting (2026)
Other vial sizes